COMPARISON TOOL

Oral vs Injectable GLP-1

A daily pill against weekly injections. Orforglipron trades some efficacy for convenience — no needle, no reconstitution, no refrigeration.

OrforglipronSemaglutideTirzepatide

Max 4 peptides

Property	Orforglipron	Semaglutide	Tirzepatide
Category	GLP-1	GLP-1	GLP-1
Type	Small molecule	Peptide	Peptide
Mechanism	Oral non-peptide GLP-1 receptor agonist	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
Status	Phase 3	FDA-approved	FDA-approved
Dosing range	3–36 mg daily	0.25–2.4 mg weekly	2.5–15 mg weekly
Frequency	Once daily (oral)	Once weekly	Once weekly
Half-life	~29–49 hours	~7 days	~5 days
Route	Oral tablet	Subcutaneous	Subcutaneous
Onset	2–4 weeks for appetite reduction	1–4 weeks for appetite reduction	1–4 weeks for appetite reduction
Studied for	Weight management Type 2 diabetes No injections	Weight management Type 2 diabetes Appetite control Cardiovascular risk	Weight management Type 2 diabetes Appetite control
Key risks	Nausea Vomiting Diarrhea Constipation	Nausea Vomiting Diarrhea Constipation	Nausea Vomiting Diarrhea Constipation
Storage	Room temperature	Refrigerated (2–8 °C); use within the pharmacy beyond-use date	Refrigerated (2–8 °C); use within the pharmacy beyond-use date
Available at G1	Not currently carried. Ask a provider	Not currently carried. Ask a provider	Not currently carried. Ask a provider
Tools	Dosage calculator →	Dosage calculator →	Dosage calculator →

PROPERTY COMPARISON · RADAR

Editorial profile scores (0–10) for orientation — not clinical measurements.

TYPICAL DOSE RANGES

Orforglipron3 mg – 36 mg

Semaglutide250 mcg – 2.4 mg

Tirzepatide2.5 mg – 15 mg

Typical per-dose range on a logarithmic scale. Your provider sets your dose.

For educational purposes only. Consult a licensed provider before starting any peptide protocol.